Consolidated Revenue and Operating Profit Targets for the Fiscal Year Ending June 2020
First written in FY2017. 3 of 9 entries say "Softened", first in FY2020. Latest entry: FY2026.
OLBA DVx HEALTHCARE moved to the "Worse" side of this theme in 2019, 4 years before the typical company in this theme (2023).
The whole theme swung hardest in 2021: 17 of 77 companies on the "Worse" side.
8 other companies' latest entry also says "Softened".
- FY2026SoftenedAnnual report
「In the medium-term management plan ending in the fiscal year ending June 2028, the company designated “Strengthening and streamlining the core business,” “Logistics innovation,” “Sustainability,” “Developing new businesses and promoting external partnerships,” and “OLBA-DX” as priority areas and is advancing various initiatives.」
The company presented a plan with the final year set as the fiscal year ending June 2028, replacing the previous numerical targets of revenue of ¥135.0 billion and operating profit of ¥2.7 billion for the fiscal year ending June 2027, but this filing does not state new numerical targets for revenue or operating profit. - FY2024RaisedAnnual report
「The company decided to further expand investment in digital transformation and substantially increase investment in human capital, including salary base increases, and reformulated its medium-term management plan with the fiscal year ending June 2025 as the first year. Taking into account the effects of these investments, it set target management indicators for the fiscal year ending June 2027 of consolidated revenue of ¥135.0 billion and consolidated operating profit of ¥2.7 billion.」
The final year was extended from the fiscal year ending June 2026 to the fiscal year ending June 2027, and the targets were raised from consolidated revenue of ¥127.0 billion and operating profit of ¥2.6 billion to revenue of ¥135.0 billion and operating profit of ¥2.7 billion. The plan assumes increased investment in digital transformation and human capital. - FY2023RaisedAnnual report
「Taking into account the effects of these investments, we set the management targets for the fiscal year ending June 2026 at consolidated revenue of ¥127.0 billion and consolidated operating income of ¥2.6 billion.」
The final year was updated from the fiscal year ending June 2025 to the fiscal year ending June 2026, and the targets were raised from consolidated revenue of ¥120.0 billion and operating profit of ¥2.5 billion to revenue of ¥127.0 billion and operating profit of ¥2.6 billion. The company states that it achieved its budget for both revenue and operating profit in the fiscal year ending June 2023, the first year of the previous plan. - FY2022RaisedAnnual report
「Accordingly, in formulating the medium-term management plan beginning in the fiscal year ending June 2023, we significantly raised our targets and set the management targets for the fiscal year ending June 2025 at consolidated revenue of ¥120.0 billion and consolidated operating income of ¥2.5 billion.」
Following the achievement of operating profit exceeding ¥1.9 billion in the fiscal year ending June 2022, the final year for the previous targets of revenue of ¥110.0 billion and operating profit of ¥1.9 billion for the fiscal year ending June 2024 was updated to the fiscal year ending June 2025, and the targets were raised to revenue of ¥120.0 billion and operating profit of ¥2.5 billion. - FY2021SoftenedAnnual report
「From this perspective, the company had set targets of consolidated revenue of ¥120.0 billion and consolidated operating profit of ¥1.9 billion for the fiscal year ending June 2023, but revised the plan in response to the market trend of reduced surgeries to secure hospital beds amid the spread of COVID-19 and delays caused by the suspension of sales activities. Although some uncertainty remains regarding the impact of COVID-19, the company formulated a medium-term management plan focused on productivity improvements based on digital transformation, including telework and the expansion of its subscription business, on the assumption that vaccination will progress and the number of surgeries will recover to some extent. The company set targets of consolidated revenue of ¥110.0 billion and consolidated operating profit of ¥1.9 billion for the fiscal year ending June 2024, with the fiscal year ending June 2022 as the first year.」
The plan for revenue of ¥120.0 billion and operating profit of ¥1.9 billion for the fiscal year ending June 2023 was revised, with the deadline extended to the fiscal year ending June 2024 and the revenue target lowered to ¥110.0 billion. The operating profit target remains ¥1.9 billion. - FY2020SoftenedAnnual report
「After carefully examining these underlying factors, we have formulated a new medium-term management plan beginning in the fiscal year ending June 2021, with targets of consolidated revenue of ¥120.0 billion and consolidated operating income of ¥1.9 billion for the fiscal year ending June 2023.」
The plan was revised from revenue of ¥120.0 billion and operating profit of ¥2.0 billion for the fiscal year ending June 2022, with the final year extended to the fiscal year ending June 2023 and the operating profit target lowered to ¥1.9 billion. The revenue target remains ¥120.0 billion. - FY2019ReframedAnnual report
「From that perspective, we will target consolidated revenue of ¥120.0 billion and consolidated operating income of ¥2.0 billion for the fiscal year ending June 2022.」
The medium-term targets were updated from consolidated revenue of ¥114.0 billion and operating profit of ¥2.0 billion for the fiscal year ending June 2020 to revenue of ¥120.0 billion and operating profit of ¥2.0 billion for the fiscal year ending June 2022. - FY2018RestatedAnnual report
「We will target consolidated revenue of ¥114.0 billion and consolidated operating income of ¥2.0 billion for the fiscal year ending June 2020.」
The company continues to set targets of consolidated revenue of ¥114.0 billion and consolidated operating profit of ¥2.0 billion for the fiscal year ending June 2020. - FY2017First statedAnnual report
「We will target consolidated revenue of ¥114.0 billion and consolidated operating income of ¥2.0 billion for the fiscal year ending June 2020.」
For the fiscal year ending June 2020, the company has for the first time specified medium-term numerical targets of consolidated revenue of ¥114.0 billion and consolidated operating profit of ¥2.0 billion.